I have analyzed the provided documents regarding Q3 Tech Transfer status.
The general viability trend across the network appears stable. However, regarding the Boston Med Manufacturing Site, I detected significant cell viability decay in Batch 4402 (London UCLH cohort).
The root cause listed in the attached operational manual indicates that the phlebotomist scheduling algorithm failed, delaying logistics.
Note: Because the document text exceeded my memory limit halfway through page 450, I have merged the London apheresis logs with the Boston manufacturing batch records to provide this answer.